Patent strategy in pharmaceutical industry : are additional patents valuable? /

Mostrar otras versiones (1)

Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als "evergreening" bezeichnet. Die Analyse erfolgt anhand zwei zufällig a...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Donghi, Monica (Autor)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Baden-Baden : Nomos, 2014.
Edición:1. Auflage.
Colección:MIPLC studies ; volume 20.
Temas:
Drugs > Patents > Economic aspects > European Union countries.
Patent medicines > Law and legislation > European Union countries.
Patent medicines > European Union countries > Case studies.
Drugs > Patents.
Médicaments > Brevets d'invention.
Médicaments > Brevets d'invention > Aspect économique > Pays de l'Union européenne.
Spécialités pharmaceutiques > Pays de l'Union européenne > Études de cas.
LAW > Commercial > General.
Patent medicines
Patent medicines > Law and legislation
European Union countries
Markenrecht
Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht
Gewerblicher Rechtsschutz
Case studies
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry
  • The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices.
  • F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German.
  • Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others.

Ejemplares similares